Insights

Vulnerable customer tech CoMentis, Inc. develops analytics and guidance tools to identify and support vulnerable customers in financial services and legal advisory contexts, indicating a potential cross-sell of risk assessment and compliance software to wealth tech firms, mortgage services, and estate planning platforms.

Regtech collaboration Recent partnerships with JustGroup, HUB Group, SimplyBiz, Pensionhelp, and Arken show active engagement with regulatory technology providers and advisory networks, suggesting opportunities to offer mental capacity and vulnerability assessment solutions to additional compliance-led distributors and platforms.

Cross‑industry traction Despite being a biotechnology R&D company, CoMentis’ software and analytics reach across financial planning, will-writing, and legal services demonstrates a versatile product fit for sectors requiring guardian/mental capacity screening, enabling expansions into fintech, insurtech, and legal tech markets.

Strategic funding posture With total funding around capital ranges implying growth capacity and revenue in the mid tens of millions, there is appetite for scalable software deployments; this suggests targeting larger partner ecosystems and channel partners to accelerate adoption while managing integration complexity.

Headquarters as access point Headquartered in South San Francisco with a fokus on CNS drug discovery, CoMentis sits near the broader Bay Area innovation hub, offering proximity to AI, biotech IT vendors, and life sciences platforms for potential co-development, data workflow integrations, and joint go-to-market initiatives.

CoMentis, Inc. Tech Stack

CoMentis, Inc. uses 8 technology products and services including jsDelivr, Open Graph, WordPress, and more. Explore CoMentis, Inc.'s tech stack below.

  • jsDelivr
    Content Delivery Network
  • Open Graph
    Content Management System
  • WordPress
    Content Management System
  • NameBright
    Domain Name Services
  • yepnope.js
    Javascript Frameworks
  • PHP
    Programming Languages
  • reCAPTCHA
    Security
  • Adobe Fonts
    Web Fonts

Media & News

CoMentis, Inc.'s Email Address Formats

CoMentis, Inc. uses at least 1 format(s):
CoMentis, Inc. Email FormatsExamplePercentage
FLast@comentis.comJDoe@comentis.com
100%

Frequently Asked Questions

What is CoMentis, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
CoMentis, Inc.'s official website is comentis.com and has social profiles on LinkedInCrunchbase.

How much revenue does CoMentis, Inc. generate?

Minus sign iconPlus sign icon
As of August 2026, CoMentis, Inc.'s annual revenue is estimated to be $10M - $25M.

What is CoMentis, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
CoMentis, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CoMentis, Inc. have currently?

Minus sign iconPlus sign icon
As of August 2026, CoMentis, Inc. has approximately 21 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Scientific Officer: M. T.Vice President Corporate Finance: G. M.Member Of Scientific Advisory Board: E. C.. Explore CoMentis, Inc.'s employee directory with LeadIQ.

What industry does CoMentis, Inc. belong to?

Minus sign iconPlus sign icon
CoMentis, Inc. operates in the Biotechnology Research industry.

What technology does CoMentis, Inc. use?

Minus sign iconPlus sign icon
CoMentis, Inc.'s tech stack includes jsDelivrOpen GraphWordPressNameBrightyepnope.jsPHPreCAPTCHAAdobe Fonts.

What is CoMentis, Inc.'s email format?

Minus sign iconPlus sign icon
CoMentis, Inc.'s email format typically follows the pattern of FLast@comentis.com. Find more CoMentis, Inc. email formats with LeadIQ.

How much funding has CoMentis, Inc. raised to date?

Minus sign iconPlus sign icon
As of August 2026, CoMentis, Inc. has raised $108M in funding. The last funding round occurred on Apr 19, 2016 for $4.5M.

When was CoMentis, Inc. founded?

Minus sign iconPlus sign icon
CoMentis, Inc. was founded in 2006.
CoMentis, Inc. logo

CoMentis, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

CoMentis, Inc. is a biotechnology research company focused on discovering and developing small-molecule drugs aimed at central nervous system disorders. Located in South San Francisco, California, the firm operates within a specialized field that seeks to address neurological and related conditions through drug development. The company partners with advisory and clinical regulation technology providers to support vulnerable or at-risk client populations, reflecting its engagement with tools that assist professionals in managing care processes. CoMentis’ activities appear to center on leveraging scientific research to advance treatment options, with a business footprint that includes collaboration and technology integration across related service sectors. The organization is based in the San Francisco Bay Area and maintains a presence in the biotechnology ecosystem there.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2006
Employees
11-50

Section iconFunding & Financials

  • $108M

    CoMentis, Inc. has raised a total of $108M of funding over 5 rounds. Their latest funding round was raised on Apr 19, 2016 in the amount of $4.5Mas a series_e.

  • $10M - $25M

    CoMentis, Inc.'s revenue is estimated to be in the range of $10M - $25M

Section iconFunding & Financials

  • $108M

    CoMentis, Inc. has raised a total of $108M of funding over 5 rounds. Their latest funding round was raised on Apr 19, 2016 in the amount of $4.5Mas a series_e.

  • $10M - $25M

    CoMentis, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.